NYSE:RCUSArcus Biosciences Stock Price, Forecast & News

Arcus Biosciences' stock was trading at $16.97 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RCUS shares have increased by 28.2% and is now trading at $21.75.
View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Arcus Biosciences.

Arcus Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Arcus Biosciences.

Arcus Biosciences Inc (NYSE:RCUS) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by $0.35. Arcus Biosciences had a negative net margin of 745.18% and a negative return on equity of 69.61%.
View Arcus Biosciences' earnings history.

6 analysts have issued 1-year target prices for Arcus Biosciences' shares. Their forecasts range from $21.00 to $48.00. On average, they anticipate Arcus Biosciences' stock price to reach $38.25 in the next twelve months. This suggests a possible upside of 75.9% from the stock's current price.
View analysts' price targets for Arcus Biosciences.

News articles about RCUS stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Arcus Biosciences earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about Arcus Biosciences.

Arcus Biosciences saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 4,140,000 shares, an increase of 23.2% from the July 15th total of 3,360,000 shares. Based on an average daily trading volume, of 831,600 shares, the short-interest ratio is currently 5.0 days. Approximately 13.9% of the shares of the stock are short sold.
View Arcus Biosciences' Short Interest.

Some companies that are related to Arcus Biosciences include FibroGen (FGEN), Amicus Therapeutics (FOLD), Biohaven Pharmaceutical (BHVN), HYPERA S A/S (HYPMY), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), Opko Health (OPK), Arena Pharmaceuticals (ARNA), BridgeBio Pharma (BBIO), ChemoCentryx (CCXI), GW Pharmaceuticals PLC- (GWPH), PTC Therapeutics (PTCT), Insmed (INSM), Principia Biopharma (PRNB) and Agios Pharmaceuticals (AGIO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics (HZNP), Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE), Amarin (AMRN), VBI Vaccines (VBIV), Protalix Biotherapeutics (PLX), Vanda Pharmaceuticals (VNDA) and Aduro BioTech (ADRO).

(RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Arcus Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Victory Capital Management Inc. (1.94%), TimesSquare Capital Management LLC (1.92%), Candriam Luxembourg S.C.A. (0.48%), Assenagon Asset Management S.A. (0.32%), Platinum Investment Management Ltd. (0.19%) and Parallel Advisors LLC (0.19%). Company insiders that own Arcus Biosciences stock include Juan C Jaen, Kathryn E Falberg, Terry J Rosen and William Grossman.
View institutional ownership trends for Arcus Biosciences.

RCUS stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Platinum Investment Management Ltd., and Parallel Advisors LLC.
View insider buying and selling activity for Arcus Biosciences.

RCUS stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., TimesSquare Capital Management LLC, Candriam Luxembourg S.C.A., Assenagon Asset Management S.A., Asymmetry Capital Management L.P., Vident Investment Advisory LLC, Vident Investment Advisory LLC, and Bessemer Group Inc.. Company insiders that have bought Arcus Biosciences stock in the last two years include Juan C Jaen, Kathryn E Falberg, Terry J Rosen, and William Grossman.
View insider buying and selling activity for Arcus Biosciences.

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RCUS stock can currently be purchased for approximately $21.75.

Arcus Biosciences has a market capitalization of $1.00 billion and generates $15 million in revenue each year. The company earns $-84,710,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Arcus Biosciences employs 108 workers across the globe.

The official website for Arcus Biosciences is www.arcusbio.com.

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]